116 related articles for article (PubMed ID: 24337320)
21. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
Mestdagh P; Fredlund E; Pattyn F; Schulte JH; Muth D; Vermeulen J; Kumps C; Schlierf S; De Preter K; Van Roy N; Noguera R; Laureys G; Schramm A; Eggert A; Westermann F; Speleman F; Vandesompele J
Oncogene; 2010 Mar; 29(9):1394-404. PubMed ID: 19946337
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1.
Wu H; Li W; Zhang M; Zhu S; Zhang D; Wang X
J Cancer Res Ther; 2016 Oct; 12(Supplement):68-71. PubMed ID: 27721258
[TBL] [Abstract][Full Text] [Related]
23. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
24. Expression of ADAM12 is regulated by E2F1 in small cell lung cancer.
Li Z; Wang Y; Kong L; Yue Z; Ma Y; Chen X
Oncol Rep; 2015 Dec; 34(6):3231-7. PubMed ID: 26503019
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es).
Farina AR; Cappabianca L; Mackay AR; Tiberio A; Tacconelli A; Tessitore A; Frati L; Martinotti S; Gulino A
Cell Growth Differ; 1997 Jul; 8(7):789-800. PubMed ID: 9218873
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional activation of the senescence regulator Lsh by E2F1.
Niu J; Chen T; Han L; Wang P; Li N; Tong T
Mech Ageing Dev; 2011 Apr; 132(4):180-6. PubMed ID: 21453717
[TBL] [Abstract][Full Text] [Related]
27. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells.
Lin RJ; Lin YC; Yu AL
Mol Carcinog; 2010 Aug; 49(8):719-27. PubMed ID: 20623644
[TBL] [Abstract][Full Text] [Related]
28. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
29. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
30. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
31. MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.
Beckers A; Van Peer G; Carter DR; Mets E; Althoff K; Cheung BB; Schulte JH; Mestdagh P; Vandesompele J; Marshall GM; De Preter K; Speleman F
Oncotarget; 2015 Mar; 6(7):5204-16. PubMed ID: 25294817
[TBL] [Abstract][Full Text] [Related]
32. MCPIP1 ribonuclease can bind and cleave
Nowak I; Boratyn E; Student S; Bernhart SF; Fallmann J; Durbas M; Stadler PF; Rokita H
RNA Biol; 2021 Jan; 18(1):144-156. PubMed ID: 32757706
[TBL] [Abstract][Full Text] [Related]
33. Alien inhibits E2F1 gene expression and cell proliferation.
Tenbaum SP; Papaioannou M; Reeb CA; Goeman F; Escher N; Kob R; von Eggeling F; Melle C; Baniahmad A
Biochim Biophys Acta; 2007 Sep; 1773(9):1447-54. PubMed ID: 17570542
[TBL] [Abstract][Full Text] [Related]
34. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.
Bettinsoli P; Ferrari-Toninelli G; Bonini SA; Prandelli C; Memo M
BMC Cancer; 2017 May; 17(1):352. PubMed ID: 28525978
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional activation of pref-1 by E2F1 in 3T3 L1 cells.
Shen YN; Kim YM; Yun CH; Moon YS; Kim SH
BMB Rep; 2009 Oct; 42(10):691-6. PubMed ID: 19874716
[TBL] [Abstract][Full Text] [Related]
36. E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells.
Cao JX; Li SY; An GS; Mao ZB; Jia HT; Ni JH
Biochem Biophys Res Commun; 2014 Jul; 450(1):470-5. PubMed ID: 24909689
[TBL] [Abstract][Full Text] [Related]
37. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells.
Wu M; Seto E; Zhang J
Oncotarget; 2015 May; 6(13):11252-63. PubMed ID: 25816777
[TBL] [Abstract][Full Text] [Related]
38. An E2F1-HOXB9 transcriptional circuit is associated with breast cancer progression.
Zhussupova A; Hayashida T; Takahashi M; Miyao K; Okazaki H; Jinno H; Kitagawa Y
PLoS One; 2014; 9(8):e105285. PubMed ID: 25136922
[TBL] [Abstract][Full Text] [Related]
39. miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14.
Xiang X; Mei H; Zhao X; Pu J; Li D; Qu H; Jiao W; Zhao J; Huang K; Zheng L; Tong Q
Oncotarget; 2015 Sep; 6(26):22452-66. PubMed ID: 26084291
[TBL] [Abstract][Full Text] [Related]
40. E2F1 somatic mutation within miRNA target site impairs gene regulation in colorectal cancer.
Lopes-Ramos CM; Barros BP; Koyama FC; Carpinetti PA; Pezuk J; Doimo NTS; Habr-Gama A; Perez RO; Parmigiani RB
PLoS One; 2017; 12(7):e0181153. PubMed ID: 28704519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
